Triple action eye drops launched for dry eye

Article

Allergan has announced the UK launch of the Optive Plus eye drops for treating severe dry eye symptoms in three different ways.

Allergan has announced the UK launch of the Optive Plus eye drops for treating severe dry eye symptoms in three different ways.

The treatment includes lipid-enhancing technology for the protection and stabilization of the lipid layer to help seal in moisture and reduce tear evaporation. Optive Plus features OsmoMax technology to moisturise and lubricate the eye surface. It also contains molecules that the company claims can penetrate deeper into the eye and hydrate corneal epithelial cells.

A recent study (Allergan data on file AG9965-001) involving 47 people suffering from dry eye demonstrated that the eye drops were safe and efficient in treating dry eye symptoms. Optive Plus showed a favourable tolerability profile.

Professor Alan Tomlinson, Department of Vision Sciences, Glasgow Caledonian University, said, “Dry eye can be a real problem for patients and in some cases can cause serious irritation, especially in patients suffering with moderate to severe dry eye symptoms. Optive Plus provides a clinically effective treatment that delivers relief from irritation, reduces tear evaporation and helps treat the underlying causes of dry eye, and will be a useful addition to the treatments we can offer to our patients.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.